Meta-regression analysis using study-level characteristics in relation to CR rate
| Variables . | Univariate analysis . | Multivariate analysis . | ||||||
|---|---|---|---|---|---|---|---|---|
| Coefficient . | Standard error . | 95% CI . | P value . | Coefficient . | Standard error . | 95% CI . | P value . | |
| CAR T-cell therapy∗ | 0.1554 | 0.0372 | 0.0824-0.2283 | <.0001 | 0.1901 | 0.0408 | 0.1102-0.2700 | <.0001 |
| Median age, y | −0.0107 | 0.0060 | −0.0224 to −0.0010 | .0734 | 0.0057 | 0.0059 | −0.0059 to 0.0173 | .3366 |
| Transformed lymphoma, % | −0.6213 | 0.3430 | −1.2937 to 0.0510 | .0701 | −0.0547 | 0.2811 | −0.6056 to 0.4961 | .8456 |
| Double-hit or triple-hit lymphoma, % | −0.6870 | 0.3953 | −1.4618 to −0.0877 | .0822 | −0.8101 | 0.2459 | −1.2920 to −0.3282 | .001 |
| Age ≥65 y, % | −0.1665 | 0.1911 | −0.5410 to 0.2080 | .3835 | NA | NA | NA | NA |
| Stage III-IV, % | −0.1739 | 0.3433 | −0.8468 to −0.4989 | .6124 | NA | NA | NA | NA |
| ≥3 previous lines of treatment, % | −0.3759 | 0.3389 | −1.0403 to 0.2884 | .2673 | NA | NA | NA | NA |
| Prior ASCT, % | −0.1020 | 0.2379 | −0.5682 to 0.3642 | .6681 | NA | NA | NA | NA |
| Refractory to last prior treatment, % | −0.0382 | 0.2334 | −0.4956 to 0.4193 | .8701 | NA | NA | NA | NA |
| Variables . | Univariate analysis . | Multivariate analysis . | ||||||
|---|---|---|---|---|---|---|---|---|
| Coefficient . | Standard error . | 95% CI . | P value . | Coefficient . | Standard error . | 95% CI . | P value . | |
| CAR T-cell therapy∗ | 0.1554 | 0.0372 | 0.0824-0.2283 | <.0001 | 0.1901 | 0.0408 | 0.1102-0.2700 | <.0001 |
| Median age, y | −0.0107 | 0.0060 | −0.0224 to −0.0010 | .0734 | 0.0057 | 0.0059 | −0.0059 to 0.0173 | .3366 |
| Transformed lymphoma, % | −0.6213 | 0.3430 | −1.2937 to 0.0510 | .0701 | −0.0547 | 0.2811 | −0.6056 to 0.4961 | .8456 |
| Double-hit or triple-hit lymphoma, % | −0.6870 | 0.3953 | −1.4618 to −0.0877 | .0822 | −0.8101 | 0.2459 | −1.2920 to −0.3282 | .001 |
| Age ≥65 y, % | −0.1665 | 0.1911 | −0.5410 to 0.2080 | .3835 | NA | NA | NA | NA |
| Stage III-IV, % | −0.1739 | 0.3433 | −0.8468 to −0.4989 | .6124 | NA | NA | NA | NA |
| ≥3 previous lines of treatment, % | −0.3759 | 0.3389 | −1.0403 to 0.2884 | .2673 | NA | NA | NA | NA |
| Prior ASCT, % | −0.1020 | 0.2379 | −0.5682 to 0.3642 | .6681 | NA | NA | NA | NA |
| Refractory to last prior treatment, % | −0.0382 | 0.2334 | −0.4956 to 0.4193 | .8701 | NA | NA | NA | NA |
NA, not applicable.
Vs bispecific antibody.